title: Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
abstract: Considerable progress has been recently made in the treatment of elderly patients with multiple myeloma (MM). In Europe the combination of thalidomide with melphalan and prednisone and of bortezomib with melphalan and prednisone are 2 standards of care for frontline therapy for elderly patients. In United States the combination of lenalidomide and dexamethasone is the preferred option in this setting. This article focuses on more recent therapeutic approaches in older MM patients, not eligible for high-dose therapy and autologous stem cell transplantation.
authors.affiliation: Hematology Department, UMR892, University Hospital, Place Ricordeau, Nantes 44093, France. Electronic address: philippe.moreau@chu-nantes.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Hematology Department, University Hospital, Rue du Morvan, Nancy 54511, France.
authors.forename: Cyrille
authors.initials: C
authors.lastname: Hulin
authors.affiliation: Hematology Department, University Hospital, Avenue Lambret, Lille 59037, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D008558:Melphalan; D011241:Prednisone
keywords: Elderly patients; Multiple myeloma; Novel agents; Therapy